Targeting EGFR with inhibitors such as gefitinib, lapatinib and erlotinib has shown limited effectiveness in prostate cancer and more recent studies reveal that the extracellular release of EGFR through exosomes may be the culprit [78,79]. Here, EGFR is linked to prostate carcinoma.